| NCT06479239 |
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer |
| NCT06148298 |
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer |
| NCT05132504 |
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer |
| NCT03322995 |
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial |
| NCT02600949 |
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer |
| NCT05975593 |
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial |
| NCT05720338 |
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? |
| NCT03257033 |
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
| NCT01915225 |
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer |
| NCT03334708 |
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma |
| NCT02757859 |
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery |
| NCT07023731 |
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation |
| NCT07491445 |
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
| NCT05969860 |
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
| NCT06904378 |
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT04048278 |
Lidocaine Infusion in Pancreatic Cancer |
| NCT04115254 |
Stereotactic Magnetic Resonance Guided Radiation Therapy |
| NCT03551951 |
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow |
| NCT01950572 |
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma |
| NCT04789486 |
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer |
| NCT05922930 |
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer |
| NCT05053971 |
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors |
| NCT07226856 |
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma |
| NCT05417594 |
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies |
| NCT04678648 |
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies |
| NCT03919292 |
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca |
| NCT03260842 |
Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer |
| NCT06937996 |
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- |
| NCT06984562 |
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer |
| NCT04074135 |
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors |
| NCT02838836 |
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers |
| NCT06989437 |
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue |
| NCT06673017 |
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT05086250 |
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer |
| NCT05128890 |
Evaluation of Resection Techniques for Pancreatic Tumors |
| NCT06411691 |
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer |
| NCT05776524 |
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer |
| NCT04751435 |
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients |
| NCT07488676 |
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors |
| NCT07118176 |
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers |
| NCT03935893 |
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers |
| NCT07478185 |
Prehab for Pancreatic Cancer Surgery |
| NCT06698458 |
Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer |
| NCT03492151 |
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions |
| NCT05225428 |
Video Education With Result Dependent dIsclosure |
| NCT04075305 |
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study |
| NCT04503265 |
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies |
| NCT03175224 |
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors |
| NCT06040541 |
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors |
| NCT07542041 |
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens |
| NCT02021604 |
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma |
| NCT05391126 |
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care |
| NCT05914987 |
Determining Individualized Cancer Therapy in Pancreatic Cancer |
| NCT05005403 |
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
| NCT07283705 |
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer |
| NCT07270237 |
A Study of Multiparametric Ultrasound Imaging Methods |
| NCT07148128 |
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. |
| NCT06381154 |
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer |
| NCT06843551 |
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation |
| NCT02775461 |
Pancreas Registry and High Risk Registry |
| NCT06271291 |
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts |
| NCT07186296 |
EXoPERT EMERALD Clinical Study |
| NCT04275557 |
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas |
| NCT05053555 |
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies |
| NCT07087054 |
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen |
| NCT06445062 |
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors |
| NCT06885697 |
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma |
| NCT07354919 |
Axelopran for Advanced Cancer in Patients Receiving Opioids |
| NCT05932862 |
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors |
| NCT06447662 |
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. |
| NCT06454383 |
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer |
| NCT04890613 |
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation |
| NCT06291324 |
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment |
| NCT07033689 |
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) |
| NCT06595160 |
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy |
| NCT04924075 |
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
| NCT06695845 |
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors |
| NCT01102556 |
PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease |
| NCT04485286 |
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury |
| NCT02393703 |
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer |
| NCT05275075 |
Identify microRNAs in Cachexia in Pancreatic Carcinoma |
| NCT04665947 |
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer |
| NCT04858334 |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
| NCT07214298 |
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT06051695 |
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression |
| NCT03492671 |
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer |
| NCT05517811 |
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection |
| NCT03937453 |
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus |
| NCT06440005 |
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors |
| NCT02000089 |
The Cancer of the Pancreas Screening-5 CAPS5)Study |
| NCT06673329 |
Brodalumab in the Treatment of Immune-Related Adverse Events |
| NCT04119024 |
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors |
| NCT01416714 |
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy |
| NCT06205849 |
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer |
| NCT05733000 |
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors |
| NCT06564571 |
Artificial Intelligence in Endoscopic Ultrasound |
| NCT04157127 |
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma |
| NCT05687123 |
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors |
| NCT06151223 |
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer |
| NCT07318051 |
Sample Collection for Ongoing Research and Product Evaluation Study |
| NCT03608631 |
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation |
| NCT07307664 |
Increasing Germline Genetic Testing for Patients With Cancer |
| NCT06239194 |
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors |
| NCT04291651 |
UCSF PANC Cyst Registry |
| NCT05376592 |
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma |
| NCT00912717 |
Pancreatic Adenocarcinoma Gene Environment Risk Study |
| NCT04858009 |
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis |
| NCT02674100 |
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry |
| NCT03568630 |
Blood Markers of Early Pancreas Cancer |
| NCT06998940 |
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations |
| NCT06412510 |
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT |
| NCT04150042 |
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells |
| NCT06651580 |
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study |
| NCT07030348 |
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study |
| NCT05245500 |
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
| NCT06182072 |
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT03454035 |
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors |
| NCT05624918 |
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma |
| NCT07554560 |
Nutrition Intervention for Pancreatic Cancer |
| NCT05254171 |
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
| NCT07076121 |
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) |
| NCT04990609 |
EUS-RFA PANCARDINAL-1 Trial |
| NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
| NCT07126158 |
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma |
| NCT06782555 |
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab |
| NCT06710132 |
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) |
| NCT05766748 |
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer |
| NCT04005690 |
Targeted Pathway Inhibition in Patients With Pancreatic Cancer |
| NCT05518903 |
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma |
| NCT06385925 |
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
| NCT04172532 |
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer |
| NCT06760819 |
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) |
| NCT03384238 |
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery |
| NCT06073431 |
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia |
| NCT07049055 |
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer |
| NCT02012699 |
Integrated Cancer Repository for Cancer Research |
| NCT05837767 |
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue |
| NCT07249775 |
A First-in-Human Study of FID-022 in Solid Tumor Patients |
| NCT05687188 |
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations |
| NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
| NCT05961982 |
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study |
| NCT06173310 |
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer |
| NCT07259317 |
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
| NCT03050268 |
Familial Investigations of Childhood Cancer Predisposition |
| NCT06582017 |
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma |
| NCT04158635 |
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer |
| NCT00001276 |
Diagnosing and Treating Low Blood Sugar Levels |
| NCT05679674 |
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer |
| NCT03556228 |
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma |
| NCT03190941 |
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients |
| NCT05379985 |
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS |
| NCT06731998 |
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery |
| NCT05365893 |
PHL Treatment in Pancreatic Cancer |
| NCT03823144 |
Intravital Microscopy in Human Solid Tumors |
| NCT05006131 |
Pancreatic Cancer Screening for At-risk Individuals |
| NCT05040360 |
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors |
| NCT05141513 |
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma |
| NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
| NCT05477576 |
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
| NCT07409272 |
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer |
| NCT06958328 |
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer |
| NCT07349537 |
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors |
| NCT05366881 |
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease |
| NCT06941857 |
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer |
| NCT04406831 |
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer |
| NCT06122896 |
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals |
| NCT06593431 |
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial |
| NCT07089940 |
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT07229313 |
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT06576115 |
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer |
| NCT06340620 |
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope |
| NCT07254091 |
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer |
| NCT07145255 |
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors |
| NCT06172478 |
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors |
| NCT04683315 |
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples |
| NCT00899626 |
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients |
| NCT05365581 |
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer |
| NCT06079346 |
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer |
| NCT06648434 |
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT07252232 |
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07300150 |
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors |
| NCT07223047 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies |
| NCT06524973 |
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers |
| NCT07199764 |
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer |
| NCT05334069 |
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection |
| NCT06747845 |
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy |
| NCT03460769 |
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) |
| NCT03977233 |
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer |
| NCT06411795 |
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy |
| NCT06228599 |
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence |
| NCT06483555 |
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel |
| NCT06242470 |
A Study of MGC026 in Participants With Advanced Solid Tumors |
| NCT07549958 |
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) |
| NCT04753879 |
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
| NCT02843945 |
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source |
| NCT05296421 |
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer |
| NCT06922591 |
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients |
| NCT04975217 |
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer |
| NCT06388967 |
Pancreatic Cancer Detection Consortium |
| NCT07114939 |
FTT PET/CT in Pancreatic Neuroendocrine Tumors |
| NCT06663072 |
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors |
| NCT07481383 |
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer |
| NCT04477343 |
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT05227326 |
AOH1996 for the Treatment of Refractory Solid Tumors |
| NCT04907643 |
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes |
| NCT07043270 |
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC |
| NCT06202066 |
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas |
| NCT05625529 |
ExoLuminate Study for Early Detection of Pancreatic Cancer |
| NCT06360354 |
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) |
| NCT06465069 |
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors |
| NCT07324096 |
A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer |
| NCT06263088 |
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. |
| NCT04429542 |
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
| NCT06400472 |
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors |
| NCT02598349 |
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas |
| NCT04588025 |
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas |
| NCT07562152 |
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
| NCT04981119 |
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing |
| NCT05088798 |
Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism |
| NCT05141149 |
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer |
| NCT06782932 |
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer |
| NCT01954992 |
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer |
| NCT00830557 |
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders |
| NCT06807437 |
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula |
| NCT03704662 |
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma |
| NCT06639724 |
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer |
| NCT07173257 |
PROMs After Pancreatectomy |
| NCT04473794 |
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts |
| NCT06252545 |
Promoting CT Engagement for Pancreatic Cancer With App |
| NCT05997056 |
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors |
| NCT06158139 |
Autologous CAR-T Cells Targeting B7-H3 in PDAC |
| NCT01102569 |
Pancreatic Cancer Genetics |
| NCT07189195 |
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma |
| NCT06001268 |
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) |
| NCT06244771 |
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors |
| NCT03484299 |
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma |
| NCT06995898 |
The Vanguard Study: Testing a New Way to Screen for Cancer |
| NCT07591571 |
To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC |
| NCT05411094 |
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer |
| NCT06128551 |
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors |
| NCT07124611 |
A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer |
| NCT05297734 |
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer |
| NCT04930991 |
High Dose Omeprazole in Patients With Pancreatic Cancer |
| NCT05013216 |
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer |
| NCT06906562 |
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations |
| NCT01365169 |
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" |
| NCT05799274 |
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors |
| NCT04421820 |
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours |
| NCT05394259 |
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer |
| NCT07522073 |
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT07127874 |
A Study of PHN-012 in Patients With Advanced Solid Tumors |
| NCT06835569 |
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations |
| NCT06910657 |
IDOV-Immune for Advanced Solid Tumors |
| NCT02478892 |
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk |
| NCT05764720 |
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach |
| NCT06423326 |
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer |
| NCT03250078 |
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals |
| NCT07458347 |
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation |
| NCT05941507 |
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors |
| NCT06736717 |
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer |
| NCT07165132 |
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. |
| NCT06298916 |
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer |
| NCT07124000 |
DESTINY-PANTUMOUR04 |
| NCT06973564 |
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration |
| NCT06423963 |
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer |
| NCT07020221 |
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors |
| NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
| NCT05723107 |
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07219238 |
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) |
| NCT06065371 |
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy |
| NCT04674267 |
Resilience and Equity in Aging, Cancer, and Health (REACH) |
| NCT05241249 |
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma |
| NCT07090499 |
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors |
| NCT04543071 |
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma |
| NCT07213791 |
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors |
| NCT05058846 |
Pilot Study of Pancreatic Cancer Screening |
| NCT06943755 |
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors |
| NCT06084013 |
Use Of Indocyanine Green In Pancreas Surgery |
| NCT02361320 |
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer |
| NCT04851119 |
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors |
| NCT07066657 |
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors |
| NCT05076760 |
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors |
| NCT03452774 |
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
| NCT06831136 |
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma |
| NCT02886247 |
Pancreatic Cancer Registry: For Any Person With a Personal or Family History |
| NCT07157033 |
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. |
| NCT05743049 |
Collection of Circulating Biomarkers in Pancreatic Cancer |
| NCT06881992 |
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism |
| NCT06850623 |
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer |
| NCT04970056 |
Pancreatic Cancer Early Detection Consortium |
| NCT04605913 |
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC |
| NCT05462496 |
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer |
| NCT04239573 |
Comparing Two Methods to Follow Patients With Pancreatic Cysts |
| NCT05052671 |
ctDNA Assay in Patients With Resectable Pancreatic Cancer |
| NCT02584244 |
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers |
| NCT04115163 |
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer |
| NCT07226154 |
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer |
| NCT07030257 |
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors |
| NCT07450859 |
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT05497531 |
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers |
| NCT06600906 |
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer |
| NCT06723236 |
A Study of MGC028 in Participants With Advanced Solid Tumors |
| NCT04956640 |
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) |
| NCT07563738 |
A 2-part Phase 1/2 Open-label Trial on ODM-212 |
| NCT05746182 |
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms |
| NCT06861088 |
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer |
| NCT05356117 |
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial |
| NCT03652428 |
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) |
| NCT06605430 |
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer |